SecBot SecBot

CELC

Celcuity Inc.
Nasdaq· Services-Medical Laboratories· Inc. DE· CIK 0001603454 Healthcare & Medical Devices
$60.57 −3.80 (−5.90%)
Nov 16 4:00 PM ET · prev $64.37
Market cap
$3.2B
Mid cap
Consensus
Buy
95% Buy or better · 19 analysts
Median target
$150.00
+148% · range $130.00–177.00
1 year
−34.3%
from $92.23 · Nov 17
30 days
+6.0%
from $57.12
52-week range
$56.58–144.98
−58% from high · low Oct 16
Avg volume 20D
1.15M
shares / day
Short interest
10.30M
≈21.0% of shares · +0.5%
Days to cover
5.8
at average volume
Insider net
−$322.9M
0 buyers · 3 sellers · 12 mo
New fund stakes
8
Q2 2026 13F · 2 exits
Filing reports
19
analyzed by SecBot
SecBot read BULLISH 12 reports · 90 days
Balance 0 bearish · 5 bullish · 7 neutral oldest → newest, height = score
Avg score ·High conf. 7/12

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    3 insiders sold $322.9M.

  • InstitutionsBULLISH

    Q2 2026: 49 added (8 new), 15 trimmed or exited. Largest new: Hood River Capital Management $65.7M, Fuller & Thaler Asset Management, $53.8M.

  • AnalystsBULLISH

    18 of 19 rate it Buy or better. Every target is above the price.

  • Short sellersSTEADY

    Short interest +0.5% to 10.30M shares. 5.8 days to cover, ≈21.0% of shares.

  • TrendRANGE

    16% below its 50-day average.

Who's buying

13F· Q2 2026
8
new positions
2
exits
$285.6M
in new stakes
FundMoveSharesValue
STATE STREET CORPADD1,955,304$204.6M
BANK OF AMERICA CORP /DE/DOUBLED1,471,307$153.9M
TORONTO DOMINION BANKADD1,258,758$131.7M
WELLINGTON MANAGEMENT GROUP LLPDOUBLED906,595$94.8M
Point72 Asset Management, L.P.DOUBLED650,916$68.1M
Hood River Capital Management LLCNEW628,411$65.7M
FMR LLCDOUBLED548,983$57.4M
Holocene Advisors, LPADD533,147$55.8M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

19 analysts
Buy 95% rate it Buy or better
Strong Buy7Buy11Hold1Sell0Strong Sell0
12-month targets · 13 analysts

Price is below the lowest target. Median implies +148%.Targets as of Nov 16, 2026.

Recent actions
DateFirmActionRating
Nov 9, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Nov 6, 2026Guggenheim
MAINTAIN
MAINTAINBuy
Nov 2, 2026Guggenheim
MAINTAIN
MAINTAINBuy
Oct 22, 2026Cantor Fitzgerald
INITIATE
INITIATEOverweight
Oct 21, 2026TD Cowen
REITERATE
REITERATEBuy
Sep 30, 2026Needham
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$322.9M
sold · 3 insiders
DateInsiderTypeValue
Oct 7, 2026
Furcht Leo
Director
Oct 7, 2026
EXERCISE$1.9K
Oct 1, 2026
GRYSKA DAVID W
Director
Oct 1, 2026
AWARD893 sh
Aug 14, 2026
Sullivan Brian F.
Chief Executive Officer
Aug 14, 2026
AWARD120,000 sh
Aug 14, 2026
Laing Lance G.
Chief Science Officer
Aug 14, 2026
AWARD10,000 sh
Aug 14, 2026
Hahne Vicky
Chief Financial Officer
Aug 14, 2026
AWARD16,000 sh
Aug 14, 2026
Laing Lance G.
Chief Science Officer
Aug 14, 2026
AWARD20,000 sh
Aug 14, 2026
Hahne Vicky
Chief Financial Officer
Aug 14, 2026
AWARD10,000 sh
Aug 14, 2026
Sullivan Brian F.
Chief Executive Officer
Aug 14, 2026
AWARD80,000 sh

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q-$1.08-$1.08–-$1.08-16.1%$31.9M
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 30, 2026
10,303,095
shares short
+0.5%
vs prior settlement
5.8
days to cover
≈21.0%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 9, 2026 Press
Celcuity announced FDA acceptance of its sNDA for REVTORPYK (gedatolisib) in HR+/HER2- advanced breast cancer with…
Impact 5/10
Nov 9, 2026 FDA
Celcuity Announces FDA Acceptance of sNDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer
FDA assigned a PDUFA goal date of June 25, 2027 FDA assigned a PDUFA goal date of June 25, 2027
Nov 5, 2026 SEC
Celcuity reported Q3 2026 results with no product revenue as REVTORPYK shipments began on Sept 30 and revenue is…
8-K · Impact 5/10
Oct 24, 2026 Press
Celcuity presented new subgroup analyses from the Phase 3 VIKTORIA-1 study at ESMO 2026, showing gedatolisib triplet…
Impact 6/10
Oct 7, 2026 Insider
Furcht Leo acquired via exercise 250 shares
Director @ $7.60 ($1.9K)
Oct 1, 2026 Insider
GRYSKA DAVID W was granted 893 shares
Director
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
1 drug tracked · Drug pipeline →
Recent

SecBot reports

19 filings · 7 press releases · 6 bullish · 2 bearish · 2 mixed · 9 neutral
All CELC filing & press-release reports (26)